secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-071988
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Phase 3 SELVA enrollment surpasses target; cash $75.6M extends runway into H2 2027
--------------------------------------------------------------------------------

- Phase 3 SELVA for microcystic LM exceeded 40-patient enrollment; closes June 2025, top-line Q1 2026.
- Phase 2 TOIVA for cutaneous VM enrolled first patients; top-line results on track for Q4 2025.
- Cash and equivalents $75.6M at March 31, 2025; funds operations into second half of 2027.
- Net loss $8.2M ($0.74 per share) vs $2.7M loss in prior-year period; R&D $4.1M, G&A $3.8M.
- Patent granted for QTORIN rapamycin in microcystic LM; IP extends into 2038.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/0000950170-25-071988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer